PRESS RELEASES

Oregon & D.C. Pass Monumental Psychedelic Reforms Aurelius Data Looks Forward to Research Opportunities - 11/4/2020

Oregon & D.C. Pass Monumental Psychedelic Reforms
Aurelius Data Looks Forward to Research Opportunities

November 4, 2020        

Missoula, MTAurelius Data, the first patient use, risk and safety focused big data company for plant-based medicines, is thrilled to see the passage of Measure 109 in Oregon, making it the first state to legalize Psilocybin for medicinal purposes. They are also pleased to see that Washington; D.C. voters have chosen to decriminalize psychedelics.

“This is a monumental day for the psychedelic advocates and researchers, validating their findings of safety and efficacy. There are enormous therapeutic benefits for patients who choose entheogenic substances for treatment resistant depression and trauma. If a patient can replace 720 capsules of Prozac each year, with two guided psilocybin sessions, they improve their quality of life through fewer side effects from medication. 

These votes are a big step in reducing the stigma of plant and fungi-based medicines. Although only legally allowed to be used by therapists in Oregon, I believe their success will create momentum to give mental therapists life-saving tools to offer their patients. The promise of psychedelics is to release depression and trauma patients from the bondage of day-in-day-out pharmaceuticals that have crippling side effects,” said Aurelius Data CEO Julie Armstrong.

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  

Our anonymously gathered data follows HIPAA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.   

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

Aurelius Data Commends its Fellow Montana Voters on Legalizing Cannabis Legalization Opens the Door for Veterans Medical Marijuana Treatments - 11/4/2020

Aurelius Data Commends its Fellow Montana Voters on
Legalizing Cannabis
Legalization Opens the Door for Veterans Medical Marijuana Treatments

November 4, 2020        

Missoula, MTAurelius Data, the first patient use, risk and safety focused big data company for plant-based medicines, commends the voters in its home state of Montana for passing Ballot Issue CI-118 and Ballot Issue I-190 which provide for a taxing structure and to allow adults 21 and older to use, possess cannabis. 

“At Aurelius Data it is imperative to us that all consumers in need will be able to have access to the alternative treatments that they choose for better wellness, and although Montana did have a medical cannabis law on the books, a crucial population was not able to access it – our veterans. 

Ironically, our veterans are specialists who were trained to use firearms to defend our country, but under the current Montana laws, are unable to legally own a firearm and hold a medical marijuana card. Now, with the passing of the new law, the restrictions that prevented veterans from accessing a treatment known to effectively treat PTSD, are gone. Our veterans deserve access to a choice for treatment other than opioids for pain, tranquilizers for sleep, and long-term antidepressants for depression,” said Aurelius Data CEO Julie Armstrong.

Ballot Issue CI 118:

  • Amends the Montana Constitution to allow the establishment of the minimum age of 21 for legal possession, use and purchase of cannabis.

Ballot Issue I-190:

  • Legalizes possession and use of cannabis by adults 21 and older.
  • Requires the Department of Revenue to develop rules regulating cannabis businesses.
  • Imposes a 20 percent tax on cannabis sales.
  • Allows people with cannabis-related convictions to be re-sentenced or have their crimes expunged. 

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  

Our anonymously gathered data follows HIPAA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.   

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

 

Cannabis Attorney Bob Hoban Joins Aurelius Data Advisory Board - 08/09/2020

Cannabis Attorney Bob Hoban Joins Aurelius Data Advisory Board

August 9, 2020   

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, is pleased to announce Bob Hoban, the preeminent cannabis attorney is the newest member of the Aurelius Data Advisory Board. 

“Bob Hoban is widely regarded around the country as one of the foremost experts in the cannabis industry and has become a global leader championing responsible policy that benefit governments and their entrepreneurs. We could not be happier to working with a man who has helped to craft this space and understands the need for research to advance plant medicines for the betterment of society,” said Aurelius Data CEO Julie Armstrong.

“Aurelius Data understands the need to standardize data and compile it to build the research necessary to create new treatments and medicines. Wellness will be first and foremost in many people’s minds after we come out of this pandemic and we are going to need groups like Aurelius Data who are striving to make sure patients have the information they need for their wellness journeys,” said Bob Hoban.

Hoban has consistently been recognized as one of the most influential people in the global cannabis industry by a variety of organizations and publications over the course of the past ten-plus years.  Since 2013, Bob has achieved the Martindale-Hubbell AV Preeminent Peer Review Rating, awarded to only those lawyers with the highest ethical standards and professional ability.  He was recently named a “Cannabis Law Trailblazer” by the National Law Journal, and he has been consistently recognized as one of “Denver’s Top Cannabis Lawyers for nearly a decade.    

From 2010-2016, Bob served as one of the Nation’s first cannabis policy instructors at the University of Denver, where he regularly lectured regarding cannabis topics (government regulations, public policy, and research-based policy courses), and where he led a University-sanctioned research practicum concerning the efficacy of marijuana regulation; the first of its kind in the U.S.  He then taught several international travel courses concerning the emergence of the global cannabis industry. Because of this academic background, Bob has been asked to work with dozens of governments across the U.S., Asia, the E.U., and Latin America (over thirty different countries) on crafting their commercial cannabis public policy solutions (legislation and regulations). And he has served on a variety of national, state, and local task forces related to cannabis policy issues.         

In 2008, he deliberately constructed the Hoban Law Group (HLG) to become the world’s leading full-service commercial cannabis industry law firm; the first of its kind  Since that time, HLG has indeed become the world’s leading cannabis industry law firm, with offices in seventeen states and ten nations abroad, and over fifty attorneys who specialize in all aspects of the commercial practice surrounding the cannabis industry. For nearly ten years, HLG has represented the cannabis industry’s titans in every aspect of the commercial cannabis industry around the world. And he is largely responsible for the establishment and growth of the CBD industry due to his legal strategies, litigation matters, and policy efforts executed on behalf of HLG clients.    

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  

Our anonymously gathered data follows HIPAA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.   

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

COVID-19 May Be Masking Ongoing Vape Crisis - 08/04/2020

COVID-19 May Be Masking Ongoing Vape Crisis

August 4, 2020

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, finds that doctors and researches are no longer tracking e-cigarette or vaping product use-associated lung injury (EVALI) and signs of EVALI can look a lot like a COVID-19 infection.

“Serious, even deadly, vaping-linked lung injuries dominated the headlines late last year, then COVID-19 took over the news cycle. Now researchers are saying it isn’t clear if EVALI cases had been missed in early 2020 because those people with EVALI could also have had COVID-19,” said Julie Armstrong, CEO and Co-founder of Aurelius Data. 

More than ten cases of EVALI were reported in California in April, during the early days of the COVID-19 pandemic, according to a new report from the California Department of Public Health and the U.S. Centers for Disease Control and Prevention (CDC).

Teens usage of vaping has not slowed down because of COVID, but doctors may not be looking for EVALI much anymore.

According to the new CDC report, the eight California EVALI patients went to the hospital about four days after symptoms began. Their average age was 17. Six said they had vaped THC.   

The CDC stopped tracking EVALI in early 2020 because cases appeared to be waning after a September 2019 peak. But as of Feb. 18, more than 2,800 people nationwide had been hospitalized with life-threatening lung damage tied to e-cigarette use, the CDC said. Sixty-eight died.

Most patients with electronic cigarette, or vaping, product use-associated lung injury (EVALI) reported use of tetrahydrocannabinol (THC)-containing products in the three months preceding symptom onset, according to research published in the Oct. 28 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

“Right now, the country is consumed with COVID and trying to diagnose it. The problem is that the symptoms for EVALI and COVID are the same – shortness of breath, fever and chills, cough, vomiting, diarrhea, headache, dizziness, rapid heart and chest pain.”

It is not clear whether vaping increases susceptibility to the new coronavirus, but it definitely increases the risk for COVID-19 complications. 

Ultimately, it’s important to see a doctor if you use e-cigarettes and develop symptoms like cough, shortness of breath or fever—and to be honest about your vaping so you can get the right diagnosis,” added Armstrong.

 

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  

Our anonymously gathered data follows HIPAA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.   

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

Aurelius Data Pledges Dedicated Research to Diseases that Plague Minorities - 07/19/2020

Aurelius Data Pledges Dedicated Research to Diseases that Plague Minorities

July 19, 2020                                                                                                                                                          

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, works to provide patients, consumers, and healthcare providers with the best plant-based treatments and alternative wellness therapies. They have pledged that they will dedicate focused time and resources to address conditions and diseases that are not treated with culturally competent diagnosis or care in minority populations.

“The country is in the middle of a necessary cultural revolution as minority communities fight for the civil rights they deserve and the best way that we at Aurelius Data felt that we could support that movement is by doing what we do best – provide research that could help save lives. We are a data driven wellness company making sure that people have access to quality care and harm reduction strategies. 

Far too often, diseases that disproportionately affect minorities are disregarded or overlooked, and often not addressed with culturally competent strategies.  One example is that studies show that many white doctors see Black patients as less sensitive to pain than white patients, often resulting in inadequate treatment.  However the risks for minorities are higher, and far more serious, for example African Americans are 50 percent more likely to have a stroke as compared to their white adult counterparts.

Also, mental health issues like depression and anxiety can hit minorities especially hard. It can be difficult to deal with the stigma of mental illness conditions coupled with a smaller chance of getting an accurate diagnosis, creating a more vulnerable population left to struggle without proper treatment.

“Understanding the reasons for the undertreatment or diagnosis in minority populations is important, and creating a way for that feedback data to constructively create change and lead to more treatment options is our goal” said Julie Armstrong, CEO and Co-Founder of Aurelius Data.

The top 7 diseases that plague minorities more than others that Aurelius Data will focus on are:

  1. Heart Disease
  2. High Blood Pressure
  3. Cancer
  4. Diabetes
  5. Stroke
  6. Peripheral Artery Disease
  7. Sickle Cell Disease

“While many advocates have been focused on the civil justice aspects and helping to make the industry more diverse from the business perspective, we don’t feel that enough attention has been placed on looking at the health of minorities and how cannabis may help.  Perhaps our research can help bring about medical advancements for this underserved and often ignored population,” added Armstrong.

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user. 

Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.  

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

 

https://www.nih.gov/news-events/nih-research-matters/factors-contributing-higher-incidence-diabetes-black-americans

Aurelius Data Launches AuraCode to Prevent Spread of COVID-19 - 07/1/2020

Aurelius Data Launches AuraCode
to Prevent Spread of COVID-19 

AURA App Allows Patients & Dispensaries to Adapt to New Contactless Society 

July 1, 2020        

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, has launched its AuraCode. Cannabis patients can now safely and privately share sensitive information with their healthcare provider or budtender when they scan the QR AuraCode displayed on one’s mobile device, giving them a personalized, contact-free encounter.

“As many have entered the first stage of reopening, we are still encouraged to social distance especially now as many states are seeing a resurgence in COVID-19 cases, patients with pre-existing conditions need to be cautious while still having access to their medicine. AuraCode allows them to interact with their budtender but limit their interaction and still get the advice they need,” said Julie Armstrong, CEO and Co-Founder of Aurelius Data.

AuraCode is a personalized QR code and one of several features available on the AURA app. The AURA mobile app provides secure, touchless access to a patient’s health and wellness information. AURA compiles a comprehensive picture of the patient’s personal healthcare path and preferences, including their current diagnosis, prescription medications, symptoms, plant medicine usage and preferences, and efficacy of treatment regimens – all available at their fingertips.

Along with the AuraCode, there are several other features included in the AURA app:

  • My Aura: Built with commonalities from a patient’s profile and others in the Aura community, My Aura lights the path to higher efficacy and better experiences.
  • Session Impressions: Track experiences and symptoms to a build a personalized picture of a patient’s health. Compiling symptoms, strains, form factors, and how much consumed.
  • Near Me: Locational data provides patients with the closest dispensaries, adult-use shops, delivery services and licensed distributors.
  • Tailored Tools: Customizable toolsets to help manage a patient’s experience. Informative displays, suggestions, and opportunities to sync with a patient’s calendar and community activities.

“The mission of Aurelius Data is to put patients’ safety first and make sure that no harm comes to them. We know that limited interaction slows the spread of this disease and our own research into how COVID-19 is affecting cannabis patients showed that a number of them were in the extreme high-risk category of transmission. It made perfect sense that we could use our app to help them limit their exposure while getting the medicines.

We also know dispensaries are de-coupling patients from their assigned providers in some states, and we want to make patient profiles accurate, private, and portable. A personalized profiles generated by patients allow for less risk, less error in their consult, and higher customer satisfaction,” added Armstrong.

 

The Aura App is currently being release in Early Access for Android devices, it is also available in Early Access for web and iOS users via web app, https://research.aureliusdata.com/aura-pr. Public Beta is scheduled to drop August 1.

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  

Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.   

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

iCan Founder Saul Kaye Joins Aurelius Data Advisory Board - 06/9/2020

iCan Founder Saul Kaye Joins Aurelius Data
Advisory Board

June 9, 2020                                                                                                                                                           

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, is pleased to announce iCan Founder and Cannabis Influencer, Saul Kaye is the newest member of the Aurelius Data Advisory Board.

“Saul has been at the forefront of the cannabis industry for the past several years advancing medical cannabis research and building upon years of Israeli ingenuity. Aurelius Data could not be prouder to working with such an industry titian who can provide valuable feedback on the work we are doing to better understand how plant-medicines interact with traditional pharmaceuticals,” said Aurelius Data CEO Julie Armstrong.

“Aurelius Data is headed into uncharted waters, using patient perception data to mitigate side effects, find new IP and eventually cures for diseases that plague so many. I am proud to be a part of the team and looking forward to help build a platform that gives patients access to better health,” said iCan Founder Saul Kaye.

Kaye has worked in the cannabis industry for the past five years and enjoyed watching the industry develop from its infancy. He began his career over 20 years ago as a retail pharmacist. Today, he manages multiple retail and online pharmacy stores with global distribution and has founded and operated several other businesses. In 2015, he founded iCAN: israel-cannabis.com with the vision to build and develop the cannabis ecosystem in Israel. With a team of 11 strong they are fulfilling the iCAN mission to be a globally recognized Israeli company focused on the medical cannabis industry, investing in, and accelerating early-stage cannabis technologies. Kaye has created a portfolio of brands that are transforming the global cannabis economy and ecosystem, like CannaTech. Well known in the industry as one of our earliest and stand-out brands; CannaTech is a superior cannabis conference experience described as “the Davos of cannabis conferences.” He also currently runs: Israpharm, ILS and the SUBS HUB.

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user. 

Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.  

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

COVID-19 Patients Should Avoid THC - 03/19/2020

COVID-19 Patients Should Avoid THC
Potential Harmful Side Effects of Cannabis on Infected Coronavirus Patients

March 18, 2020                                                                                                                                                                 

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, cautions the public against the potential harmful side effects that can come from consuming cannabis products with Tetrahydrocannabinol (THC) if a patient is infected with COVID-19.

“We know that the epidemiology of COVID-19 is similar to the influenza virus and has a similar disease presentation. And we know that in studies[1] where THC was administered to mice with influenza, we saw an increase in viral loads and a decrease in the immune system to fight off the virus. It stands to reason that the same would hold true for Coronavirus and THC consumption could diminish the immune system of someone infected with the virus,” said Aurelius Data CEO Julie Armstrong.

More research is required to accurately map the relationship between the immune and endocannabinoid systems, but it’s well established that CBD helps to modulate autoimmune and inflammatory responses.

 “Although no clinical trials exist showing poorer outcomes in patients infected with COVID-19 who use therapeutic or recreational cannabis, the data from pre-human studies urge caution for these individuals in the face of the current viral epidemic,” notes Barry Mennen, MD. a clinician who utilizes medical cannabis in his primary care practice.

Aurelius Data has prepared a brief survey to better inform patients on how cannabis consumption affects viral infections. The questionnaire will ask a patient’s symptoms, if they are concerned about contracting COVID-19, what conditions they are currently treating with medical cannabis or other pharmaceuticals and what they feel is the effectiveness of the treatment.

The brief survey can be taken here: https://research.aureliusdata.com/COVID-19

“Medical Cannabis patients across this country are going to be affected by COVID-19 just like the rest of the population and they need to be aware of the interactions their cannabis medications could have on this disease. We are working to collect data in this under researched area and provide them with the best recommendations we can moving forward,” Armstrong added.

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user. 

Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.  Dr. Barry Mennen who is quoted, is also an adviser to Aurelius Data.

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

[1] https://www.karger.com/Article/Fulltext/481824

 

Americans for Safe Access and Aurelius Data Join Forces to Create a Research Platform to Benefit Cannabis Patients - 06/11/2019

Americans for Safe Access and Aurelius Data Join Forces to Create a Research Platform to Benefit Cannabis Patients

 

WASHINGTON, June 11, 2019 (GLOBE NEWSWIRE) — Today, Aurelius Data, Inc.(AD), the premier patient perception big data company, and Americans for Safe Access (ASA), the leading advocacy organization dedicated to ensuring safe and legal access to cannabis (marijuana) for therapeutic use and research, announced a bold new partnership to gather and analyze millions of data points from cannabis patients. 

ASA and AD both recognize that while science has made significant strides in cannabis research, there is still a significant gap in education for providers and patients. With the partnership between ASA and AD, the data gathered and analyzed will advance the role of patient use and perception to the forefront of research. Combining that knowledge with chemical product analysis, patient perceived effectiveness, efficacy, form factor, and mechanisms of action (methods of administration) will yield a much-needed educational resource for patients and caregivers, providers, and the industry.

As stated by Dr. Amy Abernathy, the Acting CIO of the Federal Drug Administration, on May 31st of this year, “Systematic studies are needed. It sounds like a number of studies are available or underway. We also wonder if real-world evidence derived from electronic health records, personal monitors, administrative data, etc. can be used to address critical questions in this space.”

Through this joint patient-first initiative, ASA and AD seek to develop a research platform that creates a culture of transparency, integrity and education through data. Aurelius Data’s proprietary AURA platform and analysis tools will compile the use, perception and biometric data of consumers, for which conditions the products are being used and then matching that data with the product’s chemical analyses, and quality information. The insights generated from the platform will be available to users through the AURA mobile application, along with a community offering product education, support and best practices. #SafeAccess

“ASA is excited to be partnering with Aurelius Data, who shares a patient-first mission,” said Debbie Churgai, Interim Director of ASA. “Creating a patient focused community through the AURA platform gives our subscribers a way to connect and discover what regimens are working for other patients, offering an opportunity for real results and lasting change through research.” #MedicalCannabis, #CannabisAdvocacy

“We are so fortunate that ASA recognizes that this partnership allows us to be stronger together and to support a goal that is dear to all of us—to create trust and consistency for patients, and provide a real pathway to effective, standardized treatments,” said Julie Armstrong, CEO of Aurelius Data, Inc. #AureliusData

“The Moonshot is to let the data lead the way to identifying novel approaches to treatment, new therapies and outcomes; All without the bias of marketing and advertising, and without the influence of sources who don’t have the patient’s best outcomes as a focus. We recognize our responsibility to the subscribership of ASA and seek to honor this collaboration through providing fresh insights and a value-added community through our AURA platform”, said Armstrong.  #BeyondTheStrain

“In that spirit, we’re very enthusiastic about the potential of this groundbreaking partnership to drive solutions and improve outcomes for cannabis patients and consumers everywhere,” said Churgai.

Americans for Safe Access
The mission of Americans for Safe Access (ASA) is to ensure safe and legal access to cannabis (marijuana) for therapeutic use and research.

ASA was founded in 2002 as a vehicle for patients to advocate for the acceptance of cannabis as medicine. With over 100,000 advocates in all 50 states, ASA is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political, social and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, research, grassroots empowerment, advocacy and services for patients, governments, medical professionals, and medical cannabis providers.

Aurelius Data, Inc
Aurelius Data, Inc. (AD) is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution.
Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the Strain and create a reliable product use and efficacy reference for cannabis users.  

ARTICLES

USA TODAY - 04/20/2020

Marijuana’s big moment: Pot stores are now essential businesses. Will legal weed go mainstream?

Trevor Hughes

USA TODAY
Published: 6:09 a.m. ET Apr. 20, 2020 Updated: 9:46 a.m. ET Apr. 20, 2020
 

DENVER — The marijuana industry  is embracing change.

Edible products and pre-rolled joints are out.  Vape concentrates  and loose “flower,” which can be packed into bongs or pipes or rolled into joints and provide more bang for the buck, are in. 

Stores are effectively closed. Instead, customers order online and pick up curbside, a major shift from when each buyer had to be personally verified by a licensed store worker. In California, stores have largely switched to an all-delivery model. 

The country’s burgeoning marijuana industry is working swiftly to adapt to its customers’ needs as the coronavirus outbreak wreaks havoc on the U.S. economy. With business owners unable to access federal bailouts because the drug remains illegally nationally and popular 4/20 events cancelled because of stay-at-home orders, sellers are pushing for new ways to reach customers and persuade lawmakers that legal weed has become a crucial industry for many Americans. 

Read more...